LVP software of the Ivenix Infusion System (IIS); LVP-SW-0004
Published March 20, 2024 · Recall initiated: May 10, 2023
Summary
FDA records medical device Class II recall Z-1283-2024, published March 20, 2024 and initiated May 10, 2023. Recalling firm: Fresenius Kabi USA, LLC; Status: Completed; Reported quantity: 6 US; Lot: UDI-DI 00811505030122 Software versions 5.2.1/5.2.2. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Retroactively reported corrections from 2023: 1) A software defect may cause an incorrect (Fail-Stop) alarm when an administration set is loaded or coupled while the pump is executing the power-up sequence. May lead to delay in therapy. 2) Alert is not annunciated informing the clinician that the bolus cannot be delivered when the entered bolus dose exceeds the Care Profile Hard Rate Max limit and Rapid Bolus is selected. May lead to over infusion. Both issues were resolved in all fielded product in software version 5.8.0, which was installed in affected units May thru August 2023.
What to do
Voluntary: Firm initiated · Other
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Fresenius Kabi USA, LLC
- Distributor
- US Nationwide distribution to the states of CA, CO, NJ, WI, UT.
- Lot
- UDI-DI 00811505030122 Software versions 5.2.1/5.2.2
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDATyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by FreseniusSeptember 2, 2026
- FDAMorphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intramuscular orAugust 26, 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL,July 29, 2026
- FDAGlycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only,July 29, 2026
- FDALVP software of the Ivenix Infusion System (IIS), LVP-SW-0004March 20, 2024
- FDACERENOVUS CEREBASE DA Guide Sheath, Part Numbers: a) GS9080SD; b) GS9090SD; c) GS9095SD; VascularMarch 20, 2024
Questions about this recall
Was LVP software of the Ivenix Infusion System (IIS); LVP-SW-0004 recalled?
Yes. FDA published recall Z-1283-2024 on March 20, 2024. Reported hazard: Retroactively reported corrections from 2023: 1) A software defect may cause an incorrect (Fail-Stop) alarm when an administration set is loaded or coupled while the pump is executing the power-up sequence. May lead to delay in therapy. 2) Alert is not annunciated informing the clinician that the bolus cannot be delivered when the entered bolus dose exceeds the Care Profile Hard Rate Max limit and Rapid Bolus is selected. May lead to over infusion. Both issues were resolved in all fielded product in software version 5.8.0, which was installed in affected units May thru August 2023.
What should I do if I have this product?
Voluntary: Firm initiated · Other